Earnings ·
Veracyte reports Q3 revenue of $151.8M, raises full-year outlook and launches $100M buyback
VCYTVeracyte, Inc.
Veracyte reported third-quarter total revenue of $151.8 million, a 15% increase year-over-year, driven by growth in its Decipher Prostate and Afirma testing platforms. GAAP net income rose to $31.5 million with diluted earnings per share of $0.38. The company raised its full-year 2026 revenue guidance to $590 million–$593 million, reflecting a 14%–15% growth rate, and announced the commencement of a new $100 million share repurchase program authorized by the Board. Veracyte operates as a global diagnostics company providing molecular tests for cancer care.